Arrhythmias & electrophysiology
Outcomes and Discriminatory Accuracy of the CHA2DS2VASc Score in Atrial Fibrillation and Cancer
Authors' conclusion
Cancer patients with AF are at a higher risk of readmission and major bleeding. The risk of ischemic stroke during readmission appears to be lower than noncancer patients.
Study context
- Population
- Atrial fibrillation (AF) patients in the National Readmission Database (2015–2019), stratified by cancer diagnosis, type and CHA2DS2VASc category4,242,630 readmitted at 30 days
- Participants
- 6,996,088 patients
- Exposure
- Cancer vs noncancer in AF patients, by CHA2DS2VASc category
- Cancern = 642,237
- Noncancern = 3,600,393reference
- Outcome
- Discriminative accuracy of the CHA2DS2VASc score for ischemic stroke (ROC, AUC)
Methodological detailsNational Readmission Database (2015-2019), hierarchical multivariable logistic regression
- National Readmission Database (2015-2019)
- Hierarchical multivariable logistic regression
Main finding
As reported in the abstract
Ischemic stroke by CHA2DS2VASc category; discriminatory accuracy · 30-day readmission
Cancer vs NoncancerAdjusted odds ratio (95% CI)P value
High risk: 1.9% vs 2.4%
0.78(0.76–0.79)
P < 0.0001Moderate risk: 0.8% vs 1.3%
0.57(0.50–0.64)
P < 0.0001Low risk: 0.4% vs 0.9%
0.46(0.34–0.62)
P < 0.0001Observational data: associations, not effects.
Further findings
High CHA2DS2VASc score
P < 0.001
30-day readmission rate
- Significantly higher in cancer vs noncancer across all CHA2DS2VASc categories
Safety
- Significantly higher in cancer vs noncancer across all CHA2DS2VASc categories
- Hematological and lung cancer had a high propensity for major bleeding
Original publication
Outcomes and Discriminatory Accuracy of the CHA2DS2VASc Score in Atrial Fibrillation and Cancer. JACC Adv. Published 16 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →